Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology  Congress

Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology Congress

- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in Atopic Dermatitis-

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that a late-breaking abstract on its open-label Phase 2a trial of ATI-2138, a potent and selective investigational oral covalent inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3), was selected for oral presentation at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, being held September 17-20, 2025, in Paris, France. The presentation will include additional results from Aclaris' Phase 2a trial in patients with moderate-to-severe atopic dermatitis (AD).

Presentation Details:

Title Molecular and Clinical Effects of oral ATI-2138, an ITK/JAK3 inhibitor, in Moderate-to-Severe Atopic Dermatitis: Sub-study of a Phase 2a Open-Label, Single-Arm Trial
Abstract ID LBA-323
Session D2T01.3A
Session Room Paris Nord
Date Thursday, September 18, 2025
Time 14:15 – 14:30 CEST
Presenter Jessica Beaziz-Tordjman, M.D., French dermatologist and senior associate researcher, Laboratory for Inflammatory Skin Diseases, Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY.

About ATI-2138

ATI-2138 is a highly potent and selective novel investigational pharmacologic agent that acts as a dual inhibitor of interleukin-2-inducible T cell kinase (ITK) and Janus kinase 3 (JAK3). ITK regulates T cell receptor signal transduction and inhibition of this kinase can affect T cell differentiation and activation. JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal transducer and activator of transcription 5 (STAT5), and regulates cytokines that signal through the IL-2 receptor common gamma chain (IL-2ϒc) to affect lymphocyte proliferation and activation. The efficacy results exhibited in preclinical animal models of inflammation and autoimmune diseases, coupled with the favorable safety, PK, and PD profile in healthy human SAD and MAD studies and the top-line results of the Phase 2a trial in AD support the potential for ATI-2138 to affect several human inflammatory diseases and further investigation of this molecule in patients with atopic and autoimmune diseases that are dependent on T cell function and/or IL-2ϒc signaling.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "may," "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding the therapeutic potential for ATI-2138. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, Aclaris' ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2024, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC Filings" page of the "Investors" section of Aclaris' website at www.aclaristx.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Therapeutics Contact:

Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ACRS
The Conversation (0)
Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

EV Resources

EV Resources Acquires 100% of High-Grade Dollar Antimony Project in Nevada, USA

EV Resources Limited (ASX:EVR) (“EVR” or “the Company”) is pleased to announce it has secured 100% ownership of the historic Dollar Antimony Project, located in Nye County, Nevada – a Tier-1 mining jurisdiction strategically located near Military Metals Corp’s Last Chance Project. The project is comprised of 8 unpatented mining claims totalling 160 acres.

Keep reading...Show less
Apollo Increases Measured and Indicated Silver Resource Estimate at Calico Project

Apollo Increases Measured and Indicated Silver Resource Estimate at Calico Project

Apollo Silver Corp. (" Apollo " or the " Company ") (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0) is pleased to announce the results of an updated independent Mineral Resource estimate ("MRE") for its Calico Silver Project ("Calico" or the "Calico Project") located in San Bernardino County, California. Total silver ("Ag") Measured & Indicated ("M&I") tonnes at the Waterloo property have increased by 61% to a total of 55 million tonnes ("Mt") at a grade of 71 grams per tonne ("gt') Ag for a total content of 125 million troy ounces ("Moz"). This represents a 14% increase in Ag ounces compared to the previous MRE (dated March 6, 2023). In addition to updating the gold resource at Waterloo, inaugural barite ("BaSO4") and zinc ("Zn") resources have been included in both the Indicated and Inferred categories.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Silver47 Highlights Expansive High-Grade Gold and Silver System at the Kennedy Project, Nevada

Silver47 Highlights Expansive High-Grade Gold and Silver System at the Kennedy Project, Nevada

Samples up to 44.5 g/t Gold, 3,037 g/t Silver, and 8.56% Copper

Silver47 Exploration Corp. (TSXV: AGA,OTC:AAGAF) (OTCQB: AAGAF) ("Silver47" or the "Company") is pleased to provide assay results from a recently completed rock sampling program at its high-grade Kennedy gold-silver Project in Nevada (the "Kennedy Project"). Results demonstrate strong prospectivity for high-grade gold and silver mineralization across the under-explored project.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Element79 Gold Corp. Announces Filing of NI 43-101 Technical Report for Gold Mountain Project, Nevada

Element79 Gold Corp. Announces Filing of NI 43-101 Technical Report for Gold Mountain Project, Nevada

(TheNewswire)

Vancouver, British Columbia September 3, 2025 TheNewswire - Element79 Gold Corp. (CSE: ELEM,OTC:ELMGF) (OTC: ELMGF) (FSE: 7YS) (the "Company" or "Element79") is pleased to announce that it has filed an independent National Instrument 43-101 ("NI 43-101") Technical Report (the "Report") for the Company's Gold Mountain Project located in the Battle Mountain Mining District of Lander County, Nevada.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Smackover Lithium Announces Positive Definitive Feasibility Study Results for its South West Arkansas Project

Smackover Lithium Announces Positive Definitive Feasibility Study Results for its South West Arkansas Project

Smackover Lithium, a Joint Venture ("JV") between Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV: SLI) (NYSE.A: SLI) and Equinor ("Equinor"), announced today the positive results of a Definitive Feasibility Study ("DFS") for its South West Arkansas ("SWA") project (the "Project" or "SWA Project").

All figures are in US dollars unless otherwise stated. All terms not otherwise defined have the meaning given to them under the CIM Definition Standards for mineral resources and mineral reserves.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and MagSense® HER2 Breast Cancer diagnostic imaging program, supporting the planned Phase 2 Clinical Trial expected to commence towards the end of 2025.

Keep reading...Show less
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less

Latest Press Releases

Related News

×